LYEL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
3.0K
-25.0%
4.0K
+100.0%
2.0K
-66.7%
6.0K
-60.0%
15.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
3.0K
-25.0%
4.0K
+100.0%
2.0K
-66.7%
6.0K
-60.0%
15.0K
Operating Expenses
48.3M
+2.0%
47.3M
+7.0%
44.3M
-65.9%
129.8M
+248.3%
37.3M
R&D
40.9M
+3.5%
39.5M
+8.0%
36.6M
-29.9%
52.2M
+85.3%
28.2M
SG&A
9.3M
-2.9%
9.6M
+0.2%
9.6M
-10.0%
10.6M
-0.7%
10.7M
Operating Income
-48295000
-2.0%
-47337000
-6.9%
-44261000
+65.9%
-129789000
-248.4%
-37253000
EBITDA
-46241000
-2.5%
-45115000
-7.6%
-41929000
+31.3%
-61060000
-76.0%
-34687000
Net Income
-45529000
-1.7%
-44755000
-85.3%
-24153000
+82.8%
-140723000
-262.3%
-38846000
EPS (Basic)
$-1.86
+3.1%
$-1.92
-74.5%
$-1.10
+83.9%
$-6.85
-221.6%
$-2.13
EPS (Diluted)
$-1.86
+3.1%
$-1.92
-74.5%
$-1.10
+83.9%
$-6.85
-221.6%
$-2.13
Shares (Diluted)
24.4M
+4.6%
23.4M
+6.8%
21.9M
+6.4%
20.6M
+12.5%
18.3M
Lyell Immunopharma (LYEL) — Financials